

WEST Search History

DATE: Friday, September 14, 2007

Hide?	<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>
		<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L6	L5 and (bromide or hydrobromide)	4
<input type="checkbox"/>	L5	L4 and (morphine near2 glucuronide)	8
<input type="checkbox"/>	L4	536/17.4.icls. or 536/17.9.ccls. or 514/32.icls. or 514/32.ccls. or 514/33.icls. or 514/33.ccls. or 514/34.icls. or 514/34.ccls.	1779
<input type="checkbox"/>	L3	5593695.pn.	1
<input type="checkbox"/>	L2	6150524.pn.	1
<input type="checkbox"/>	L1	6172206.pn.	1

END OF SEARCH HISTORY

FILE 'REGISTRY' ENTERED AT 14:15:32 ON 14 SEP 2007

EXP MORPHINE-6-GLUCURONIDE/CN
EXP MORPHINE 6 GLUCURONIDE/CN
EXP MORPHINE 6 BETA
EXP MORPHINE 6 BETA/CN
EXP MORPHINE-6-BETA/CN

L1 1 S E1

FILE 'CAPLUS' ENTERED AT 14:17:27 ON 14 SEP 2007

L2 1 S L1

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:18:17 ON 14 SEP 2007
SEA (MORPHINE-6-GLUCURONIDE) OR L1

62* FILE ADISCTI
8 FILE ADISINSIGHT
14 FILE ADISNEWS
2 FILE AGRICOLA
80 FILE ANABSTR
0* FILE ANTE
0* FILE AQUALINE
3* FILE AQUASCI
7* FILE BIOENG
551 FILE BIOSIS
8 FILE BIOTECHABS
8 FILE BIOTECHDS
72 FILE BIOTECHNO
9* FILE CABA
576* FILE CAPLUS
3* FILE CEABA-VTB
10 FILE CIN
11* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
3* FILE DDFB
352* FILE DDFU
218* FILE DGENE
13* FILE DISSABS
3* FILE DRUGB
407* FILE DRUGU
3* FILE EMBAL
790 FILE EMBASE
208* FILE ESBIODASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
1* FILE GENBANK
1* FILE HEALSAFE
42* FILE IFIPAT
20 FILE IMSDRUGNEWS
3 FILE IMSRESEARCH
0* FILE KOSMET
82* FILE LIFESCI
562 FILE MEDLINE
0* FILE NTIS
0* FILE NUTRACEUT
0* FILE OCEAN
SEA ((MORPHINE-6-GLUCURONIDE) AND (HYDROBROMIDE OR BROMIDE)) OR

0* FILE ADISCTI
0* FILE ANTE

0* FILE AQUALINE
 0* FILE AQUASCI
 0* FILE BIOENG
 2 FILE BIOSIS
 1 FILE BIOTECHABS
 1 FILE BIOTECHDS
 2 FILE BIOTECHNO
 0* FILE CABA
 13* FILE CAPLUS
 0* FILE CEABA-VTB
 0* FILE CONFSCI
 0* FILE CROPB
 0* FILE CROPU
 0* FILE DDFB
 0* FILE DDFU
 0* FILE DGENE
 0* FILE DISSABS
 0* FILE DRUGB
 3* FILE DRUGU
 0* FILE EMBAL
 9 FILE EMBASE
 2* FILE ESBIODASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 5* FILE IFIPAT
 1 FILE IMSRESEARCH
 0* FILE KOSMET
 0* FILE LIFESCI
 3 FILE MEDLINE
 0* FILE NTIS
 0* FILE NUTRACEUT
 0* FILE OCEAN
 0* FILE PASCAL
 0* FILE PCTGEN
 0* FILE PHARMAML
 0* FILE PHIC
 0* FILE PHIN
 0* FILE RDISCLOSURE
 4* FILE SCISEARCH
 1 FILE SYNTHLINE
 5 FILE TOXCENTER
 0* FILE USGENE
 33* FILE USPATFULL
 0* FILE USPATOLD
 6* FILE USPAT2
 0* FILE VETB
 0* FILE VETU
 0* FILE WATER
 8 FILE WPIDS
 0* FILE WPIFV
 8 FILE WPINDEX

L3 QUE ((MORPHINE-6-GLUCURONIDE) AND (HYDROBROMIDE OR BROMIDE)) OR

L4 FILE 'HCAPLUS' ENTERED AT 14:21:59 ON 14 SEP 2007
 L5 576 S (MORPHINE-6-GLUCURONIDE)
 L6 293526 S BROMIDE OR HYDROBROMIDE
 13 S L4 AND L5

FILE 'STNGUIDE' ENTERED AT 14:22:04 ON 14 SEP 2007

FILE 'HCAPLUS' ENTERED AT 14:22:18 ON 14 SEP 2007

FILE 'STNGUIDE' ENTERED AT 14:22:19 ON 14 SEP 2007

FILE 'HCAPLUS' ENTERED AT 14:23:14 ON 14 SEP 2007

FILE 'STNGUIDE' ENTERED AT 14:23:14 ON 14 SEP 2007

FILE 'REGISTRY' ENTERED AT 14:33:02 ON 14 SEP 2007

EXP MORPHINE HYDROBROMIDE/CN

L7 1 S E3

FILE 'CAPLUS' ENTERED AT 14:33:32 ON 14 SEP 2007

L8 1 S L7/THU

L9 5 S L7

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:15:32 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9
DICTIONARY FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp morphine-6-glucuronide/cn

E1	1	MORPHINE-6-B-D-GLUCURONIDE HYDROBROMIDE/CN
E2	1	MORPHINE-6-3H/CN
E3	0 -->	MORPHINE-6-GLUCURONIDE/CN
E4	1	MORPHINE-6-SUCCINATE/CN
E5	1	MORPHINE-6-SULFONIC ACID/CN
E6	1	MORPHINE-7,8-T2, 7,8-DIHYDRO-/CN
E7	1	MORPHINE-ALPRENOLOL MIXT./CN
E8	1	MORPHINE-FLUPIRTINE MIXT./CN
E9	1	MORPHINE-METHYL-D3/CN
E10	1	MORPHINE-N-(METHYL-D3) HYDROCHLORIDE/CN
E11	1	MORPHINE-N-CT3/CN
E12	2	MORPHINE-N-METHYL-14C/CN

=> exp morphine 6 glucuronide/cn

E1	1	MORPHINE 3-SULFATE/CN
E2	1	MORPHINE 3-VALERATE/CN
E3	0 -->	MORPHINE 6 GLUCURONIDE/CN
E4	1	MORPHINE 6-(B-D-GLUCOPYRANOSYLCARBAMOTHIOATE)/CN
E5	1	MORPHINE 6-(HYDROGEN PHTHALATE)/CN
E6	1	MORPHINE 6-(METHYL SUBERATE)/CN
E7	1	MORPHINE 6-(P-BROMOBENZOATE)/CN
E8	1	MORPHINE 6-(P-CHLOROBENZOATE)/CN
E9	1	MORPHINE 6-(P-FLUOROBENZOATE)/CN
E10	1	MORPHINE 6-(P-HYDROXYBENZOATE)/CN
E11	1	MORPHINE 6-(P-NITROBENZOATE)/CN
E12	1	MORPHINE 6-(TERT-BUTYLDIMETHYLSILYL) ETHER/CN

=> exp morphine 6 beta

E1	7	MORPHINDOLE/BI
E2	1339	MORPHINE/BI
E3	0 -->	MORPHINE 6 BETA/BI
E4	1	MORPHINE:NADP/BI
E5	1	MORPHINECARBO/BI

E6	1	MORPHINECARBODI/BI
E7	1	MORPHINECARBODITHIO/BI
E8	1	MORPHINECARBODITHIOATO/BI
E9	1	MORPHINECARBOX/BI
E10	1	MORPHINECARBOXAMIDE/BI
E11	1	MORPHINECARBOXYL/BI
E12	1	MORPHINECARBOXYLIC/BI

=> exp morphine 6 beta/cn

E1	1	MORPHINE 3-SULFATE/CN
E2	1	MORPHINE 3-VALERATE/CN
E3	0 -->	MORPHINE 6 BETA/CN
E4	1	MORPHINE 6- (B-D-GLUCOPYRANOSYLCARBAMOTHIOATE) /CN
E5	1	MORPHINE 6- (HYDROGEN PHTHALATE) /CN
E6	1	MORPHINE 6- (METHYL SUBERATE) /CN
E7	1	MORPHINE 6- (P-BROMOBENZOATE) /CN
E8	1	MORPHINE 6- (P-CHLOROBENZOATE) /CN
E9	1	MORPHINE 6- (P-FLUOROBENZOATE) /CN
E10	1	MORPHINE 6- (P-HYDROXYBENZOATE) /CN
E11	1	MORPHINE 6- (P-NITROBENZOATE) /CN
E12	1	MORPHINE 6- (TERT-BUTYLDIMETHYLSILYL) ETHER/CN

=> exp morphine-6-beta/cn

E1	1	MORPHINE-6-B-D-GLUCURONIDE HYDROBROMIDE/CN
E2	1	MORPHINE-6-3H/CN
E3	0 -->	MORPHINE-6-BETA/CN
E4	1	MORPHINE-6-SUCCINATE/CN
E5	1	MORPHINE-6-SULFONIC ACID/CN
E6	1	MORPHINE-7,8-T2, 7,8-DIHYDRO-/CN
E7	1	MORPHINE-ALPRENOLOL MIXT./CN
E8	1	MORPHINE-FLUPIRTINE MIXT./CN
E9	1	MORPHINE-METHYL-D3/CN
E10	1	MORPHINE-N- (METHYL-D3) HYDROCHLORIDE/CN
E11	1	MORPHINE-N-CT3/CN
E12	2	MORPHINE-N-METHYL-14C/CN

=> s el

L1	1	"MORPHINE-6-B-D-GLUCURONIDE HYDROBROMIDE"/CN
----	---	--


=> d ll

L1	ANSWER 1 OF 1	REGISTRY	COPYRIGHT 2007 ACS on STN
RN	663191-69-3	REGISTRY	
ED	Entered STN:	15 Mar 2004	
CN	β-D-Glucopyranosiduronic acid, (5α,6α)-7,8-didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl, hydrobromide (9CI) (CA INDEX NAME)		

OTHER NAMES:

CN	Morphine-6-β-D-glucuronide hydrobromide
FS	STEREOSEARCH
MF	C23 H27 N O9 . Br H
SR	CA
LC	STN Files: CA, CAPLUS, IMSPATENTS, IMSRESEARCH, USPATFULL
CRN	(20290-10-2)

Absolute stereochemistry. Rotation (-).



● HBr

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
8.25	8.46

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 14:17:27 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 13 Sep 2007 (20070913/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1

L2 1 L1

=>

=> d l1 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n

=> d l2 ti abs bib

L2 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN

TI Morphine-6-glucuronide salts and stability thereof
 AB Several salts of morphine-6-glucuronide are prepared, and the hydrobromide salt (M6G.HBr) is surprisingly stable compared to other M6G salts and M6G free base. Use of M6G.HBr as a medicament, in particular as an analgesic, and methods of making M6G.HBr are described.
 AN 2004:162705 CAPLUS <<LOGINID::20070914>>
 DN 140:205122
 TI Morphine-6-glucuronide salts and stability thereof
 IN Graham, John Aitken
 PA Cenes Limited, UK
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004016633	A1	20040226	WO 2003-GB3562	20030814
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2494812	A1	20040226	CA 2003-2494812	20030814
	AU 2003255790	A1	20040303	AU 2003-255790	20030814
	EP 1537132	A1	20050608	EP 2003-787894	20030814
	EP 1537132	B1	20060104		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2006500360	T	20060105	JP 2004-528672	20030814
	AT 315041	T	20060215	AT 2003-787894	20030814
	ES 2256790	T3	20060716	ES 2003-3787894	20030814
	ZA 2005001053	A	20050829	ZA 2005-1053	20050204
	IN 2005CN00181	A	20070907	IN 2005-CN181	20050214
	NO 2005001261	A	20050311	NO 2005-1261	20050311
	US 2006166900	A1	20060727	US 2005-524149	20050628
PRAI	GB 2002-18811	A	20020814		
	WO 2003-GB3562	W	20030814		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> index bioscience

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
3.30	11.76

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.78	-0.78

CA SUBSCRIBER PRICE

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:18:17 ON 14 SEP 2007

69 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> s (morphine-6-glucuronide) or l1

62* FILE ADISCTI
8 FILE ADISINSIGHT
14 FILE ADISNEWS
2 FILE AGRICOLA
80 FILE ANABSTR
0* FILE ANTE
0* FILE AQUALINE
3* FILE AQUASCI
7* FILE BIOENG
551 FILE BIOSIS
8 FILE BIOTECHABS
8 FILE BIOTECHDS
72 FILE BIOTECHNO
9* FILE CABA
576* FILE CAPLUS
3* FILE CEABA-VTB
10 FILE CIN
11* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
3* FILE DDFB
352* FILE DDFU
218* FILE DGENE
13* FILE DISSABS
3* FILE DRUGB
407* FILE DRUGU

27 FILES SEARCHED...

3* FILE EMBAL
790 FILE EMBASE
208* FILE ESBIODBASE
0* FILE FOMAD
0* FILE FOREGE
0* FILE FROSTI
1* FILE GENBANK
1* FILE HEALSAFE
42* FILE IFIPAT
20 FILE IMSDRUGNEWS
3 FILE IMSRESEARCH
0* FILE KOSMET
82* FILE LIFESCI
562 FILE MEDLINE
0* FILE NTIS
0* FILE NUTRACEUT

<-----User Break----->

=> s ((morphine-6-glucuronide) and (hydrobromide or bromide)) or l1

0* FILE ADISCTI
0* FILE ANTE
0* FILE AQUALINE
0* FILE AQUASCI
0* FILE BIOENG
2 FILE BIOSIS
1 FILE BIOTECHABS
1 FILE BIOTECHDS
2 FILE BIOTECHNO
0* FILE CABA
13* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CONFSCI
0* FILE CROPB

0* FILE CROPU
 0* FILE DDFB
 0* FILE DDFU
 0* FILE DGENE
 0* FILE DISSABS
 24 FILES SEARCHED...
 0* FILE DRUGB
 3* FILE DRUGU
 0* FILE EMBAL
 9 FILE EMBASE
 2* FILE ESBIODASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 5* FILE IFIPAT
 1 FILE IMSRESEARCH
 0* FILE KOSMET
 0* FILE LIFESCI
 3 FILE MEDLINE
 0* FILE NTIS
 0* FILE NUTRACEUT
 0* FILE OCEAN
 0* FILE PASCAL
 0* FILE PCTGEN
 0* FILE PHARMAML
 0* FILE PHIC
 0* FILE PHIN

55 FILES SEARCHED...
 0* FILE RDISCLOSURE
 4* FILE SCISEARCH
 1 FILE SYNTHLINE
 5 FILE TOXCENTER
 0* FILE USGENE
 33* FILE USPATFULL
 0* FILE USPATOLD
 6* FILE USPAT2
 0* FILE VETB
 0* FILE VETU
 0* FILE WATER
 8 FILE WPIDS
 0* FILE WPIFV
 8 FILE WPINDEX

18 FILES HAVE ONE OR MORE ANSWERS, 69 FILES SEARCHED IN STNINDEX

L3 QUE ((MORPHINE-6-GLUCURONIDE) AND (HYDROBROMIDE OR BROMIDE)) OR L1

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	3.78	15.54
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'HCAPLUS' ENTERED AT 14:21:59 ON 14 SEP 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2007 VOL 147 ISS 13
FILE LAST UPDATED: 13 Sep 2007 (20070913/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s (morphine-6-glucuronide)

42423 MORPHINE
3953156 6
14477 GLUCURONIDE
L4 576 (MORPHINE-6-GLUCURONIDE)
(MORPHINE (W) 6 (W) GLUCURONIDE)

=> s bromide or hydrobromide

283277 BROMIDE
13325 HYDROBROMIDE
L5 293526 BROMIDE OR HYDROBROMIDE

=> s l4 and l5

L6 13 L4 AND L5

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	18.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-0.78

FILE 'STNGUIDE' ENTERED AT 14:22:04 ON 14 SEP 2007
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 7, 2007 (20070907/UP).

=> d l6 1-13 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Preparation of (S)-N-methylnaltrexones with opioid receptor binding activity for use in pharmaceutical compositions

L6 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Substituted indole compounds having NOS inhibitory activity and their

preparation and pharmaceutical composition

L6 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of complexes of morphine-6-glucuronide
complexes with phosphatidylethanolamine-binding protein (PEBP) peptides to
prolong morphine serum half-life in treatment of pain

L6 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Classification of Substrates and Inhibitors of P-Glycoprotein Using
Unsupervised Machine Learning Approach

L6 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Specific haplotypes of MDR1 gene and their use in diagnosis and therapy

L6 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Morphine-6-glucuronide salts and stability
thereof

L6 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Method and pharmaceutical composition using devazepide and surfactant with
opioid analgesic therapy

L6 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Method of treatment of patients requiring analgesia with opioid analgesics

L6 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI A Computational Ensemble Pharmacophore Model for Identifying Substrates of
P-Glycoprotein

L6 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Process for preparing morphine-6-glucuronide
and its analogues using haloglucuronate ester intermediates

L6 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI The synthesis of some analogs of morphine 6-
glucuronide through Wittig reactions upon dihydrocodeinone

L6 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI A general pattern for substrate recognition by P-glycoprotein

L6 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Quantitation of morphine, morphine-3-glucuronide, and morphine-
6-glucuronide in plasma and cerebrospinal fluid using
solid-phase extraction and high-performance liquid chromatography with
electrochemical detection

=> d l6 3 4 6 7 8 10 11 13 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L6 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
TI Use of complexes of morphine-6-glucuronide
complexes with phosphatidylethanolamine-binding protein (PEBP) peptides to
prolong morphine serum half-life in treatment of pain

AB A method of prolonging the serum half-life of morphine and its derivs. by
forming a complex with the phosphatidylethanolamine-binding protein (PEBP)
that is stable in chromaffin cells but degraded in blood plasma is
described. Morphine-6-glucuronide was found
to form a stable complex with PEBP.

AN 2006:1118897 HCAPLUS <<LOGINID::20070914>>
DN 145:465691
TI Use of complexes of morphine-6-glucuronide

complexes with phosphatidylethanolamine-binding protein (PEBP) peptides to
 prolong morphine serum half-life in treatment of pain
 IN Goumon, Yannick; Metz-Boutigue, Marie-Helene; Aunis, Dominique
 PA INSERM (Institut National de la Sante et de la Recherche Medicale), Fr.
 SO PCT Int. Appl., 62pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006111355	A1	20061026	WO 2006-EP3540	20060418
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI EP 2005-300295 A 20050419
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Classification of Substrates and Inhibitors of P-Glycoprotein Using
 Unsupervised Machine Learning Approach
 AB P-glycoprotein (P-gp), a drug efflux pump, affects the bioavailability of
 therapeutic drugs and plays a potentially important role in clin.
 drug-drug interactions. Classification of candidate drugs as substrates
 or inhibitors of the carrier protein is of crucial importance in drug
 development. The extreme diversity of substrates and the presence of
 multiple binding sites complicate the understanding of the mechanisms
 behind and hinder the development of a true, conclusive quant.
 structure-activity relationship (QSAR) for P-gp substrates. In addition,
 both inhibitors and substrates interact with the same binding site of
 P-gp. As a result, both share many common structural features. In this
 work, an unsupervised machine learning approach based on the Kohonen
 self-organizing maps (SOM) was explored, which incorporated a predefined
 set of physicochem. descriptors encoding the key mol. properties capable
 of discerning a substrate from an inhibitor. The SOM model can
 discriminate between substrates and inhibitors with an average accuracy of
 82.3%. The current results show that the SOM-based method provides a
 potential in silico model for virtual screening.

AN 2005:335682 HCAPLUS <<LOGINID::20070914>>
 DN 143:19256
 TI Classification of Substrates and Inhibitors of P-Glycoprotein Using
 Unsupervised Machine Learning Approach
 AU Wang, Yong-Hua; Li, Yan; Yang, Sheng-Li; Yang, Ling
 CS Lab of Pharmaceutical Resource Discovery, Dalian Institute of Chemical
 Physics, Graduate School, Chinese Academy of Sciences, Dalian, 116023,
 Peop. Rep. China
 SO Journal of Chemical Information and Modeling (2005), 45(3), 750-757
 CODEN: JCISD8; ISSN: 1549-9596
 PB American Chemical Society
 DT Journal
 LA English

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Morphine-6-glucuronide salts and stability thereof
 AB Several salts of morphine-6-glucuronide are prepared, and the hydrobromide salt (M6G.HBr) is surprisingly stable compared to other M6G salts and M6G free base. Use of M6G.HBr as a medicament, in particular as an analgesic, and methods of making M6G.HBr are described.
 AN 2004:162705 HCAPLUS <<LOGINID::20070914>>
 DN 140:205122
 TI Morphine-6-glucuronide salts and stability thereof
 IN Graham, John Aitken
 PA Cenex Limited, UK
 SO PCT Int. Appl., 27 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2004016633	A1	20040226	WO 2003-GB3562	20030814	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
	RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	CA 2494812	A1	20040226	CA 2003-2494812	20030814	
	AU 2003255790	A1	20040303	AU 2003-255790	20030814	
	EP 1537132	A1	20050608	EP 2003-787894	20030814	
	EP 1537132	B1	20060104			
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK		
	JP 2006500360	T	20060105	JP 2004-528672	20030814	
	AT 315041	T	20060215	AT 2003-787894	20030814	
	ES 2256790	T3	20060716	ES 2003-3787894	20030814	
	ZA 2005001053	A	20050829	ZA 2005-1053	20050204	
	IN 2005CN00181	A	20070907	IN 2005-CN181	20050214	
	NO 2005001261	A	20050311	NO 2005-1261	20050311	
	US 2006166900	A1	20060727	US 2005-524149	20050628	
PRAI	GB 2002-18811	A	20020814			
	WO 2003-GB3562	W	20030814			

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Method and pharmaceutical composition using devazepide and surfactant with opioid analgesic therapy
 AB There is described a method of treatment of a patient requiring analgesia which comprises the sep., simultaneous or sequential administration of a therapeutically effective amount of an opioid analgesic, devazepide and a surfactant. There is also described a monophasic pharmaceutical composition comprising an amount of devazepide effective in the enhancement of opioid analgesia and a pharmaceutically acceptable surfactant. The use of a surfactant is advantageous in that it improves the powder flow and/or separation properties of solid devazepide and also reduces or mitigates the undesirable side effects of opioid administration, e.g. constipation.
 AN 2003:633285 HCAPLUS <<LOGINID::20070914>>
 DN 139:159955

TI Method and pharmaceutical composition using devazepide and surfactant with
opioid analgesic therapy
IN Jackson, Karen
PA ML Laboratories PLC, UK
SO U.S. Pat. Appl. Publ., 8 pp., Cont.-in-part of U.S. Ser. No. 108,659.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003153592	A1	20030814	US 2003-349431	20030122
	US 6713470	B2	20040330		
	US 2004198723	A1	20041007	US 2002-53962	20020122
	US 2003139396	A1	20030724	US 2002-108659	20020327
	US 2004043990	A1	20040304	US 2003-410311	20030409
	US 2004167146	A1	20040826	US 2003-622492	20030721
	US 2004142959	A1	20040722	US 2004-752411	20040107
PRAI	US 2002-53962	B2	20020122		
	US 2002-108659	A2	20020327		
	GB 2002-1367	A	20020122		
	GB 2002-8129	A	20020409		
	US 2003-349431	A2	20030122		

L6 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Method of treatment of patients requiring analgesia with opioid analgesics
AB There is described a method of treatment of a patient requiring analgesia
which comprises the sep., simultaneous or sequential administration of a
therapeutically effective amount of an opioid analgesic, devazepide, and a
surfactant. There is also described a monophasic pharmaceutical composition
comprising devazepide effective in the enhancement of opioid analgesia and
a surfactant. The daily dosage of devazepide is up to 0.7 mg/kg/day.

AN 2003:590987 HCAPLUS <<LOGINID::20070914>>

DN 139:138761

TI Method of treatment of patients requiring analgesia with opioid analgesics

IN Jackson, Karen

PA Ml Laboratories Plc, UK

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English


FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003061632	A1	20030731	WO 2003-GB221	20030122
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2473884	A1	20030731	CA 2003-2473884	20030122
	EP 1467718	A1	20041020	EP 2003-708305	20030122
	EP 1467718	B1	20051123		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003007022	A	20041103	BR 2003-7022	20030122
	JP 2005521655	T	20050721	JP 2003-561577	20030122
	AT 310509	T	20051215	AT 2003-708305	20030122
	ES 2253662	T3	20060601	ES 2003-3708305	20030122

NO 2004002758	A	20040922	NO 2004-2758	20040630
IN 2004KN00923	A	20060512	IN 2004-KN923	20040702
MX 2004PA07030	A	20041011	MX 2004-PA7030	20040721
PRAI GB 2002-1367	A	20020122		
WO 2003-GB221	W	20030122		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN
 TI Process for preparing morphine-6-glucuronide
 and its analogues using haloglucuronate ester intermediates
 GI



AB This invention discloses a process for preparing morphine-6-glucuronide and related compds. (I) [R1 = (un)substituted alkyl, aryl, silyl, acyl; R2 = glycoside ester; R3 = alkyl, aryl, H, (CH2)nX where n is a integer; X = NRR4; R, R4 = H, alkyl, aryl, acyl; C(7) - C(8) linkage is olefin, dihydro, dihydroxy, hydroxyhalo, epoxy, dihalo, hydrohalo, hydrohydroxy, or olefin adducts CHX-CHY; X, Y = epoxy, halogen, hydrohalogen] using haloglucuronate esters as an intermediates in the presence of iodine or an iodonium compound. Thus, I (R1 = pivaloyl, R2 = Me β-D-(2,3,4-tripivaloyl)glucuronate, R3 = Me) was prepared by the reaction of 3-O-pivaloylmorphine and 1-deoxy-1-iodo-2,3,4-tri-O-pivaloyl-α-D-glucopyranuronate (also prepared) in presence of iodine.

AN 2000:911257 HCAPLUS <<LOGINID::20070914>>
 DN 134:56828
 TI Process for preparing morphine-6-glucuronide
 and its analogues using haloglucuronate ester intermediates
 IN Scheinmann, Feodor; Stachulski, Andrew Valentine; Ferguson, John; Law, Jane Louise
 PA UFC Limited, UK
 SO PCT Int. Appl., 20 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2000078764	A1	20001228	WO 2000-GB2232	20000620
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2375274	A1	20001228	CA 2000-2375274	20000620

EP 1200441	A1	20020502	EP 2000-938910	20000620
EP 1200441	B1	20050209		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003502427	T	20030121	JP 2001-504930	20000620
AT 288917	T	20050215	AT 2000-938910	20000620
US 6642366	B1	20031104	US 2002-19585	20020607
PRAI GB 1999-14382	A	19990621		
WO 2000-GB2232	W	20000620		
OS CASREACT 134:56828; MARPAT 134:56828				
RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD				
ALL CITATIONS AVAILABLE IN THE RE FORMAT				

L6 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

TI The synthesis of some analogs of morphine 6-glucuronide through Wittig reactions upon dihydrocodeinone

AB In preliminary studies to establish the biol. role of the glucuronide unit in morphine 6-glucuronide, a number of codeine derivs. bearing alkyl side chains appended through C-6 have been synthesized using Wittig reactions between suitable ylides and dihydrocodeinone. During the course of this work some aldolization type products of dihydrocodeinone were obtained. Attempts to introduce side chains by radical coupling reactions between bromocodides and allyltributyltin failed.

AN 1998:540981 HCAPLUS <<LOGINID::20070914>>

DN 129:330889

TI The synthesis of some analogs of morphine 6-glucuronide through Wittig reactions upon dihydrocodeinone

AU Liu, Maxson; Mahon, Mary F.; Sainsbury, Malcolm

CS Department of Chemistry, University of Bath, Claverton Down, Bath, BA2 7AY, UK

SO Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1998), (17), 2943-2952

CODEN: JCPRB4; ISSN: 0300-922X

PB Royal Society of Chemistry

DT Journal

LA English

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Quantitation of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma and cerebrospinal fluid using solid-phase extraction and high-performance liquid chromatography with electrochemical detection

AB An original, sensitive, and specific high-performance liquid chromatog. (HPLC) assay was developed for the quantitation of morphine and its two major metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G), in human plasma and cerebrospinal fluid (CSF) and in rat plasma, using hydromorphone as the internal standard. Solid-phase extraction was used to sep. morphine and its glucuronide metabolites from plasma constituents. Extraction efficiencies of morphine, M3G, and M6G from human plasma samples (0.5 mL) were 84, 87, and 88%, resp. Extraction efficiencies of morphine, M3G, and M6G did not differ significantly ($p > 0.05$) between human plasma and CSF or rat plasma. Morphine, M3G, M6G, and hydromorphone were separated on a 10 μ C8 Resolve radially compressed cartridge using a mobile phase comprising methanol:acetonitrile:phosphate buffer, (0.0125M pH 7.5; 10:10:80), in which 11 mg/L of cetyltrimethylammonium bromide (cetrimide) was dissolved. Quantitation was achieved using a single electrochem. detector at ambient temperature (23°C). Standard curves were linear over the ranges 0.020-2.190, 0.027-2.709, and 0.027-0.542 μ M for morphine, M3G, and M6G, resp. Lower limits of detection for morphine, M3G, and M6G in human plasma and CSF samples (0.5 mL) were 0.020, 0.027, and 0.027 μ M, resp.

Corresponding lower limits of detection in rat plasma (0.1 mL) were 0.102, 0.135, and 0.135 μ M, resp. Intraassay precision for low and high concns. of morphine, M3G, and M6G were <23 and <8% resp. Similarly, interassay accuracy for low and medium concns. of morphine, M3G, and M6G were <17% and were <9% for high concns.

AN 1994:472903 HCAPLUS <<LOGINID::20070914>>

DN 121:72903

TI Quantitation of morphine, morphine-3-glucuronide, and morphine-6-glucuronide in plasma and cerebrospinal fluid using solid-phase extraction and high-performance liquid chromatography with electrochemical detection

AU Wright, Andrew W. E.; Watt, Julie A.; Kennedy, Michelle; Cramond, Tess; Smith, Maree T.

CS R. Brisbane Hosp., Univ. Queensl., Brisbane, 4072, Australia

SO Therapeutic Drug Monitoring (1994), 16(2), 200-8

CODEN: TDMODV; ISSN: 0163-4356

DT Journal

LA English

=> d his

(FILE 'HOME' ENTERED AT 14:15:24 ON 14 SEP 2007)

FILE 'REGISTRY' ENTERED AT 14:15:32 ON 14 SEP 2007

EXP MORPHINE-6-GLUCURONIDE/CN

EXP MORPHINE 6 GLUCURONIDE/CN

EXP MORPHINE 6 BETA

EXP MORPHINE 6 BETA/CN

EXP MORPHINE-6-BETA/CN

L1 1 S E1

FILE 'CAPLUS' ENTERED AT 14:17:27 ON 14 SEP 2007

L2 1 S L1

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:18:17 ON 14 SEP 2007

SEA (MORPHINE-6-GLUCURONIDE) OR L1

62* FILE ADISCTI
8 FILE ADISINSIGHT
14 FILE ADISNEWS
2 FILE AGRICOLA
80 FILE ANABSTR
0* FILE ANTE
0* FILE AQUALINE
3* FILE AQUASCI
7* FILE BIOENG
551 FILE BIOSIS
8 FILE BIOTECHABS
8 FILE BIOTECHDS
72 FILE BIOTECHNO
9* FILE CABA
576* FILE CAPLUS
3* FILE CEABA-VTB
10 FILE CIN
11* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
3* FILE DDFB
352* FILE DDFU
218* FILE DGENE

13* FILE DISSABS
 3* FILE DRUGB
 407* FILE DRUGU
 3* FILE EMBAL
 790 FILE EMBASE
 208* FILE ESBIODBASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 1* FILE GENBANK
 1* FILE HEALSAFE
 42* FILE IFIPAT
 20 FILE IMSDRUGNEWS
 3 FILE IMSRESEARCH
 0* FILE KOSMET
 82* FILE LIFESCI
 562 FILE MEDLINE
 0* FILE NTIS
 0* FILE NUTRACEUT
 0* FILE OCEAN
 SEA ((MORPHINE-6-GLUCURONIDE) AND (HYDROBROMIDE OR BROMIDE)) OR

0* FILE ADISCTI
 0* FILE ANTE
 0* FILE AQUALINE
 0* FILE AQUASCI
 0* FILE BIOENG
 2 FILE BIOSIS
 1 FILE BIOTECHABS
 1 FILE BIOTECHDS
 2 FILE BIOTECHNO
 0* FILE CABA
 13* FILE CAPLUS
 0* FILE CEABA-VTB
 0* FILE CONFSCI
 0* FILE CROPB
 0* FILE CROPU
 0* FILE DDFB
 0* FILE DDFU
 0* FILE DGENE
 0* FILE DISSABS
 0* FILE DRUGB
 3* FILE DRUGU
 0* FILE EMBAL
 9 FILE EMBASE
 2* FILE ESBIODBASE
 0* FILE FOMAD
 0* FILE FOREGE
 0* FILE FROSTI
 0* FILE GENBANK
 0* FILE HEALSAFE
 5* FILE IFIPAT
 1 FILE IMSRESEARCH
 0* FILE KOSMET
 0* FILE LIFESCI
 3 FILE MEDLINE
 0* FILE NTIS
 0* FILE NUTRACEUT
 0* FILE OCEAN
 0* FILE PASCAL
 0* FILE PCTGEN
 0* FILE PHARMAML
 0* FILE PHIC
 0* FILE PHIN

0* FILE RDISCLOSURE
 4* FILE SCISEARCH
 1 FILE SYNTHLINE
 5 FILE TOXCENTER
 0* FILE USGENE
 33* FILE USPATFULL
 0* FILE USPATOLD
 6* FILE USPAT2
 0* FILE VETB
 0* FILE VETU
 0* FILE WATER
 8 FILE WPIDS
 0* FILE WPIFV
 8 FILE WPINDEX

L3 QUE ((MORPHINE-6-GLUCURONIDE) AND (HYDROBROMIDE OR BROMIDE)) OR

L4 FILE 'HCAPLUS' ENTERED AT 14:21:59 ON 14 SEP 2007
 L5 576 S (MORPHINE-6-GLUCURONIDE)
 L6 293526 S BROMIDE OR HYDROBROMIDE
 13 S L4 AND L5

FILE 'STNGUIDE' ENTERED AT 14:22:04 ON 14 SEP 2007

FILE 'HCAPLUS' ENTERED AT 14:22:18 ON 14 SEP 2007

FILE 'STNGUIDE' ENTERED AT 14:22:19 ON 14 SEP 2007

FILE 'HCAPLUS' ENTERED AT 14:23:14 ON 14 SEP 2007

FILE 'STNGUIDE' ENTERED AT 14:23:14 ON 14 SEP 2007

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	50.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 14:23:50 ON 14 SEP 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
 SESSION RESUMED IN FILE 'STNGUIDE' AT 14:32:55 ON 14 SEP 2007
 FILE 'STNGUIDE' ENTERED AT 14:32:55 ON 14 SEP 2007
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)f

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	50.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL

CA SUBSCRIBER PRICE	ENTRY 0.00	SESSION -7.02
=> file registry		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	50.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-7.02

FILE 'REGISTRY' ENTERED AT 14:33:02 ON 14 SEP 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9
 DICTIONARY FILE UPDATES: 13 SEP 2007 HIGHEST RN 947061-18-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp morphine hydrobromide/cn

E1	2	MORPHINE GLUCURONIDE/CN
E2	1	MORPHINE HYDRIODIDE, HYDRIODIDE/CN
E3	1 -->	MORPHINE HYDROBROMIDE/CN
E4	1	MORPHINE HYDROBROMIDE, DIHYDRATE/CN
E5	1	MORPHINE HYDROCHLORIDE/CN
E6	1	MORPHINE HYDROCHLORIDE MIXT. WITH SPARTEINE SULFATE AND ATRO PINE SULFATE/CN
E7	1	MORPHINE HYDROCHLORIDE TRIHYDRATE/CN
E8	1	MORPHINE HYDROCHLORIDE-ATROPINE SULFATE MIXT./CN
E9	1	MORPHINE HYDROCHLORIDE-N-ALLYLNORMORPHINE HYDROCHLORIDE-ACEP ROMAZINE MALEATE MIXTURE/CN
E10	1	MORPHINE HYDROCHLORIDE-N-ALLYLNORMORPHINE HYDROCHLORIDE-ACEP ROMAZINE MALEATE-BENZYLHARMINE HYDROCHLORIDE MIXT./CN
E11	1	MORPHINE HYDROCHLORIDE-N-ALLYLNORMORPHINE HYDROCHLORIDE-PROM AZINE HYDROCHLORIDE MIXTURE/CN
E12	1	MORPHINE HYDROCHLORIDE-N-ALLYLNORMORPHINE-ACEPROMAZINE MALEA TE MIXT./CN

=> s E3


L7 1 "MORPHINE HYDROBROMIDE"/CN

=> d 17

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2007 ACS on STN
 RN 630-81-9 REGISTRY
 ED Entered STN: 16 Nov 1984

CN Morphinan-3,6-diol, 7,8-didehydro-4,5-epoxy-17-methyl-
 (5 α ,6 α)-, hydrobromide (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN Morphine hydrobromide
 FS STEREOSEARCH
 MF C17 H19 N O3 . Br H
 LC STN Files: BEILSTEIN*, CA, CAPLUS, CHEMLIST, HSDB*, TOXCENTER, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)
 CRN (57-27-2)

Absolute stereochemistry. Rotation (-).



● HBr

5 REFERENCES IN FILE CA (1907 TO DATE)
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

7.35

57.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-7.02

FILE 'CAPLUS' ENTERED AT 14:33:32 ON 14 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 13 Sep 2007 (20070913/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 17/thu

5 L7
934038 THU/RL
L8 1 L7/THU
(L7 (L) THU/RL)

=> s 17

L9 5 L7

=> d 19 1-5 ti abs bib

L9 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Morphine alkaloids. 138. The first preparation of 6 β -bromo codeine
and morphine derivatives. Kinetic vs. thermodynamic control
AB Starting from the hydrogen halide salts of morphine and codeine derivs.,
6 β -halogeno(Cl,Br)-substituted codeine and morphine derivs. were
prepared under Mitsunobu conditions. E.g., codeine hydrochloride was
converted to 6 β -chloro-6-deoxycodine in 70% yield using DEAD and
PPh₃ in benzene.
AN 1998:148517 CAPLUS <<LOGINID::20070914>>
DN 128:230547
TI Morphine alkaloids. 138. The first preparation of 6 β -bromo codeine
and morphine derivatives. Kinetic vs. thermodynamic control
AU Simon, Csaba; Hosztafi, Sandor; Makleit, Sandor
CS Alkaloida Chem. Company Ltd., Tiszavasvari, H-4440, Hung.
SO Journal of Chemical Research, Synopses (1997), (12), 437
CODEN: JRPSDC; ISSN: 0308-2342
PB Royal Society of Chemistry
DT Journal
LA English
OS CASREACT 128:230547
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
TI Pharmaceutical bilayer tablets containing morphine
AB A bilayer tablet comprises a layer of morphine, poly(alkylene oxide) and
poly(vinylpyrrolidone); and an expandable layer of coated granules of a
higher mol. weight poly(alkylene oxide) and a hydroxyalkyl cellulose.
Morphine sulfate pentahydrate (I) 432, poly(ethylene oxide) 963, and
poly(vinyl pyrrolidone) 90 g were mixed, followed by addition of 404 g
denatured anhydrous alc. The prepared wet granulation was passed through a 20
mesh screen and allowed to dry at room temperature for 18 h, then passed
through
a 16 mesh screen. The screened granulation was transferred to a planetary
mixer and with constant blending 14.9 g of calcium stearate was added to
produce the therapeutic composition The composition compressed into 50 mg
tablets
containing 70 mg I.
AN 1995:958458 CAPLUS <<LOGINID::20070914>>
DN 124:37702
TI Pharmaceutical bilayer tablets containing morphine
IN Merrill, Sonya; Ayer, Atul D.; Hwang, Paul; Kuczynski, Anthony L.
PA Alza Corp., USA
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5460826	A	19951024	US 1994-266075	19940627
	US 5593695	A	19970114	US 1995-449620	19950524
	CA 2186260	A1	19960104	CA 1995-2186260	19950614
	CA 2186260	C	20070731		
	WO 9600066	A1	19960104	WO 1995-US7727	19950614
	W: AU, CA, FI, JP, KR, MX, NO, NZ				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9527761	A	19960119	AU 1995-27761	19950614
	AU 688524	B2	19980312		
	EP 767663	A1	19970416	EP 1995-923087	19950614
	EP 767663	B1	20020403		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10502086	T	19980224	JP 1995-503263	19950614
	AT 215372	T	20020415	AT 1995-923087	19950614
	ES 2172587	T3	20021001	ES 1995-923087	19950614
	US 5667805	A	19970916	US 1996-726107	19961004
	FI 9605203	A	19961223	FI 1996-5203	19961223
	NO 9605540	A	19961227	NO 1996-5540	19961223
	NO 311326	B1	20011119		
PRAI	US 1994-266075	A3	19940627		
	US 1995-449620	A1	19950524		
	WO 1995-US7727	W	19950614		

L9 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

TI Method using narcotic analgesic and noroxymorphone quaternary derivative for reducing emesis and nausea induced by the administration of an emesis-causing agent

GI



AB The title method comprises administration of an effective amount of a narcotic analgesic and a noroxymorphone quaternary derivative I (R = allyl or related radical, cyclopropyl-Me, propargyl; X = anion of an acid) prior to, simultaneous with, or after administration of an emesis-causing agent different from the narcotic analgesic. The method is highly effective in preventing or relieving nausea and emesis induced by anticancer drugs or by apomorphine. The combination of methylnaltrexone and morphine was 100% effective in preventing cisplatin-induced emesis in dogs.

AN 1992:400900 CAPLUS <<LOGINID::20070914>>

DN 117:900

TI Method using narcotic analgesic and noroxymorphone quaternary derivative for reducing emesis and nausea induced by the administration of an emesis-causing agent

IN Goldberg, Leon I.

PA Arch Development Corp., USA.

SO U.S., 4 pp. Cont. of U.S. Ser. No. 312,117, abandoned.

CODEN: USXXAM

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5102887	A	19920407	US 1990-540884	19900615
	AU 654275	B2	19941103	AU 1991-76319	19910430
	AU 9176319	A	19921126		
PRAI	US 1989-312117	B1	19890217		
OS	MARPAT 117:900				

L9 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

TI Analytical study of alkaloids

AB The HBr, HCl, HI, H₂SO₄ and picric acid crystalline salt of the free bases atropine, cocaine, codeine, emetine, hyoscyamine, morphine, papaverine, and quinine were prepared and their optical properties under ordinary, parallel polarized, and convergent polarized light were examined microscopically. High degrees of reproducibility and exactitude were observed. No crystalline salts were obtained with silicotungstic acid. The ir spectra of the free bases were recorded.

AN 1974:441384 CAPLUS <<LOGINID::20070914>>

DN 81:41384

TI Analytical study of alkaloids

AU Arenas de Castano, Isabel; Veloza, Gloria S.

CS Fac. Cienc., Univ. Nac. Colombia, Bogota, Colombia

SO Revista Colombiana de Ciencias Quimico-Farmaceuticas (1973), 2(2), 105-26
CODEN: RCQFAQ; ISSN: 0034-7418

DT Journal

LA Spanish

L9 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

TI Action of physostigmine, morphine, cyclopentolate, and homatropine on the secretion and outflow of aqueous humor in the rabbit eye

AB The i.v. injection of 0.5 mg physostigmine salicylate (I) [57-64-7]/kg in rabbits caused a marked decrease in intraocular pressure, which seemed to be due to the decrease in inflow of aqueous humor, but 3-day topical application of 50 µl 1% I twice daily had no effect on the intraocular pressure or fluid dynamics. I.v. injection of 7.5 mg morphine-HBr [630-81-9]/kg increased both the inflow rate and the outflow facility of the eye. Cyclopentolate-HCl [5870-29-1] (50 mg/kg) and homatropine-HBr [51-56-9] (0.5 mg/kg) did not decrease the outflow facility. Cyclopentolate applied either i.v. or topically increased both the inflow rate and the outflow facility slightly, while i.v.-applied homatropine had no effect on the intraocular fluid dynamics but when applied topically slightly increased the intraocular pressure. None of the drugs caused any significant change in the Na-K-ATPase [9000-83-3] activity in the ciliary body-iris, but I and morphine markedly reduced magnesium ATPase [9000-83-3] activity. I did not decrease Mg-ATPase activity when the eye had been sympathectomized 7 days before I administration. The effect of I on Mg-ATPase was possibly mediated by way of the sympathetic nervous system.

AN 1973:52649 CAPLUS <<LOGINID::20070914>>

DN 78:52649

TI Action of physostigmine, morphine, cyclopentolate, and homatropine on the secretion and outflow of aqueous humor in the rabbit eye

AU Uusitalo, Risto

CS Dep. Anat., Univ. Helsinki, Helsinki, Finland

SO Acta Physiologica Scandinavica (1972), 86(2), 239-49

CODEN: APSCAX; ISSN: 0001-6772

DT Journal

LA English